In the last decade, Seattle Genetics made significant strides in the field of cancer research. Today, the company has recruited some of the leading researchers and scientists to undertake comprehensive studies on cancer and aging. The firm started as a small agency. With its continued progress in developing viable cancer therapies, Seattle Genetics has managed to expand the scope of its research to include aging-related diseases. Within five years of operations, Seattle Genetics’ stock price had tripled, indicating the firm’s impact in the industry.
Clay Siegall heads Seattle Genetics. Since he started his profession in biomedical studies, Clay has always been interested in improving the lives of cancer patients. He is a graduate of George Washington University where he earned his PhD in Genetics. He started his career at Bristol-Meyers Squibb Pharmaceuticals Research Institute by working as a senior research investigator. He rose through the ranks to become a principal scientist. Later, he joined the National Cancer Institute where he worked as a biotechnology and staff fellow.
Over the years, Siegall has helped the company to make successful breakthroughs in cancer research. Clay has a genuine desire to assist cancer patients. It is for this reason that Dr. Clay has zeroed in on developing viable cancer drugs to lengthen the lives of cancer patients. Under Siegall’s visionary leadership, the company was able to develop the first antibody-drug conjugates known as ADCETRIS.
About Clay Siegall
Clay Siegall is a revered scientist. Over the years, he has specialized in targeted cancer therapies. Clay is one of the founders of Seattle Genetics, which was established in 1998. He serves as the CEO and president of company. In addition, Clay is the chairman of the board. He founded the company on the foundation of rigorous research, scientific innovation, drug development and passion for assisting patients. Presently, Siegall is leading the company in developing a pipeline of proprietary ADCs for cancer treatment.
Over the years, Clay has helped Seattle Genetics to enter into several strategic partnerships with GlaxoSmithKline, AbbVie, and Genentech for its ADC technology. These licenses have generated over $350 million. Siegall has also guided the firm in capital-raising activities. To this end, he has secured more than $1.2 for the corporation through private and public financing.